ASH 2018 News From Genentech

  • December 14, 2018

This year at the American Society of Hematology (ASH) Annual Meeting, Genentech presented data for ten medicines in more than 70 abstracts, including 25 oral presentations [press release].

Highlighted data included new data from three Venclexta® (venetoclax) combination studies demonstrating deep responses in chronic lymphocytic leukemia and acute myeloid leukemia, two of the most common types of leukemia. Longer follow-up in both studies have shown deep responses and remission, supporting the basis of the Venclexta FDA approvals this year [press release].

For additional Genentech perspective, visit the Hematology hub on gene.com.

Who’s Online

Profile picture of FLASCO